PV Bulletin
European Medicines AgencyEU

Updated eCTD v4.0 technical validation criteria

Revision of technical validation rules for eCTD v4.0 submissions impacting PSURs, RMPs, and other safety-related filings.

PV Impact Brief

Urgency: HighConfidence: high
Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country ComplianceICSR
Action needed

All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.

Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Technical Guidance
Policy status
Revised
Publication date
2026-07-15
Policy change
Revision of technical validation rules for eCTD v4.0 submissions, which applies to PSURs, RMPs, and other safety-related filings.

Key changes

New validation checks and bug fixes for v4.0 electronic submissions.

Affected workflows

Country ComplianceICSR

PV impact

Requires technical alignment of electronic PV submissions (PSUR/RMP) with the updated validation criteria.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jul 15, 2026

Full briefing

What changed

Revised technical validation rules for eCTD v4.0 submissions, requiring compliance for PSURs, RMPs, and other related filings.

Why it matters

These updates are critical for ensuring the accuracy and compliance of electronic submissions, impacting regulatory processes across the EU.

Practical implication

All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.

#Safety Signals#European Medicines Agency (EMA)#reporting_requirement#Revised#policy-change#firecrawl-policy-agent#Technical Guidance

Related updates for your role

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Reflection paper on particulars for safety signals for (traditional) herbal medicinal products

Urgency: High

Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward
publicCenter for Drug Evaluation (CDE), National Medical Products Administration (NMPA) · China · Updated Jul 14, 2026

Technical Guidelines for Communication on Real-World Evidence Supporting the Extension of Pediatric Indications for Marketed Drugs (Draft for Comments)

Urgency: High

Sponsors must implement early communication strategies with the CDE regarding RWE study plans as a prerequisite for pediatric indication extension submissions.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Consultation
Read impact briefarrow_forward
publicHealth Canada · Canada · Updated Jul 15, 2026

Order Providing for Reliance on Foreign Regulatory Authority Decisions for Certain Drugs (Ministerial Reliance Order)

Urgency: High

Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

Country ComplianceSignal ManagementRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward
publicFood and Drug Administration · United States · Updated Jul 13, 2026

Psychedelic Drugs: Considerations for Clinical Investigations

Urgency: High

Clinical safety and pharmacovigilance teams must implement new safety monitoring protocols and ensure adequate assessment of abuse potential as stipulated in the guidance.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guideline
Read impact briefarrow_forward